These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 28602600)

  • 1. Influence of the dual combination of silymarin and (-)-epigallocatechin gallate, natural dietary flavonoids, on the pharmacokinetics of oxcarbazepine in rats.
    Ferreira A; Rodrigues M; Marques A; Falcão A; Alves G
    Food Chem Toxicol; 2017 Aug; 106(Pt A):446-454. PubMed ID: 28602600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silymarin as a flavonoid-type P-glycoprotein inhibitor with impact on the pharmacokinetics of carbamazepine, oxcarbazepine and phenytoin in rats.
    Ferreira A; Rodrigues M; Meirinho S; Fortuna A; Falcão A; Alves G
    Drug Chem Toxicol; 2021 Sep; 44(5):458-469. PubMed ID: 31020859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro screening of dual flavonoid combinations for reversing P-glycoprotein-mediated multidrug resistance: Focus on antiepileptic drugs.
    Ferreira A; Santos AO; Falcão A; Alves G
    Food Chem Toxicol; 2018 Jan; 111():84-93. PubMed ID: 29122665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique.
    Fortuna A; Alves G; Falcão A; Soares-da-Silva P
    Epilepsia; 2012 Mar; 53(3):529-38. PubMed ID: 22372629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: An in vitro evaluation with focus on antiepileptic drugs.
    Ferreira A; Rodrigues M; Fortuna A; Falcão A; Alves G
    Food Res Int; 2018 Jan; 103():110-120. PubMed ID: 29389596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
    Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
    Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
    Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
    Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
    Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
    Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
    Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
    Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine.
    Marchi N; Guiso G; Rizzi M; Pirker S; Novak K; Czech T; Baumgartner C; Janigro D; Caccia S; Vezzani A
    Epilepsia; 2005 Oct; 46(10):1613-9. PubMed ID: 16190932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.
    Chen X; Gu E; Wang S; Zheng X; Chen M; Wang L; Hu G; Cai JP; Zhou H
    J Chromatogr Sci; 2016 Mar; 54(3):334-42. PubMed ID: 26499119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.
    Clinckers R; Smolders I; Michotte Y; Ebinger G; Danhof M; Voskuyl RA; Della Pasqua O
    Br J Pharmacol; 2008 Dec; 155(7):1127-38. PubMed ID: 18836479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
    Ahmad A; Garnett WR
    Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine.
    Keränen T; Sorri A; Moilanen E; Ylitalo P
    Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine.
    Hainzl D; Parada A; Soares-da-Silva P
    Epilepsy Res; 2001 May; 44(2-3):197-206. PubMed ID: 11325575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity.
    Clinckers R; Smolders I; Meurs A; Ebinger G; Michotte Y
    J Pharmacol Exp Ther; 2005 Aug; 314(2):725-31. PubMed ID: 15860570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
    Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
    Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.
    Mintzer S; Boppana P; Toguri J; DeSantis A
    Epilepsia; 2006 Mar; 47(3):510-5. PubMed ID: 16529614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of valproic acid on the pharmacokinetic profile of oxcarbazepine in the rat.
    Matar KM; Nicholls PJ; Bawazir SA; al-Hassan MI; Tekle A
    Pharm Acta Helv; 1999 Feb; 73(5):247-50. PubMed ID: 10085790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.